UNSPSC 51282934: Orbifloxacin

This classification denotes a quinolone antibiotic with the molecular formula C19H20F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 660932TPY6, chemically known as 1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-5,6,8-trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid but generally known as orbifloxacin, which bears US NIH Compound Identifier 60605. European Medicines Agency schedules Orbifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09454MIG.

UNSPSC 51282934 Orbifloxacin, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The code's taxonomy name references a specific veterinary fluoroquinolone antibiotic, yet the recent opportunities posted under this code reflect broader pharmaceutical and medical supply procurement — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and first-aid supplies for emergency response — rather than orbifloxacin itself or veterinary pharmaceuticals. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), fire departments (City of Tampa), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The geographic spread spans Florida, Texas, and Minnesota, with cooperative purchasing mechanisms extending to participating jurisdictions across multiple states.

Recent opportunities under the code include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (IFB60459723LAS); the City of Tampa's invitation to bid for medical and first aid supplies totaling approximately $700,000 for the Tampa Fire Department Rescue Division, due March 13, 2026 (26P00145), designated as a small local business enterprise set-aside with a 5 percent bid discount; the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs, posted April 3, 2026 (HHS0017013); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026 (S1070000015802). The mismatch between the code's specific pharmaceutical naming and the actual scope of recent solicitations suggests either misclassification in state and local procurement tagging or a code that does not reflect current buying patterns in this commodity family.